Global Biologics and Biosimilars Market Size, Manufacturers, Opportunities and Forecast to 2030
Summary
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, The global Biologics and Biosimilars market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars.
The Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, The global Biologics and Biosimilars market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars.
The Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- United Laboratories
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Others
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Biologics and Biosimilars Market Size Estimates and Forecasts (2019-2030)
1.2.2 Global Biologics and Biosimilars Sales Estimates and Forecasts (2019-2030)
1.3 Biologics and Biosimilars Market by Type
1.3.1 Monoclonal Antibodies
1.3.2 Interferon
1.3.3 Erythropoietin
1.3.4 Insulin
1.3.5 Vaccines
1.3.6 Others
1.4 Global Biologics and Biosimilars Market Size by Type
1.4.1 Global Biologics and Biosimilars Market Size Overview by Type (2019-2030)
1.4.2 Global Biologics and Biosimilars Historic Market Size Review by Type (2019-2024)
1.4.3 Global Biologics and Biosimilars Forecasted Market Size by Type (2025-2030)
1.5 Key Regions Market Size by Type
1.5.1 North America Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
1.5.2 Europe Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
1.5.3 Asia-Pacific Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
1.5.4 Latin America Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
1.5.5 Middle East and Africa Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
2 GLOBAL MARKET DYNAMICS
2.1 Biologics and Biosimilars Industry Trends
2.2 Biologics and Biosimilars Industry Drivers
2.3 Biologics and Biosimilars Industry Opportunities and Challenges
2.4 Biologics and Biosimilars Industry Restraints
3 MARKET COMPETITIVE LANDSCAPE BY COMPANY
3.1 Global Top Players by Biologics and Biosimilars Revenue (2019-2024)
3.2 Global Top Players by Biologics and Biosimilars Sales (2019-2024)
3.3 Global Top Players by Biologics and Biosimilars Price (2019-2024)
3.4 Global Biologics and Biosimilars Industry Company Ranking, 2022 VS 2023 VS 2024
3.5 Global Biologics and Biosimilars Key Company Manufacturing Sites & Headquarters
3.6 Global Biologics and Biosimilars Company, Product Type & Application
3.7 Global Biologics and Biosimilars Company Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Biologics and Biosimilars Market CR5 and HHI
3.8.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2023
3.8.3 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier
4 BIOLOGICS AND BIOSIMILARS REGIONAL STATUS AND OUTLOOK
4.1 Global Biologics and Biosimilars Market Size and CAGR by Region: 2019 VS 2023 VS 2030
4.2 Global Biologics and Biosimilars Historic Market Size by Region
4.2.1 Global Biologics and Biosimilars Sales in Volume by Region (2019-2024)
4.2.2 Global Biologics and Biosimilars Sales in Value by Region (2019-2024)
4.2.3 Global Biologics and Biosimilars Sales (Volume & Value), Price and Gross Margin (2019-2024)
4.3 Global Biologics and Biosimilars Forecasted Market Size by Region
4.3.1 Global Biologics and Biosimilars Sales in Volume by Region (2025-2030)
4.3.2 Global Biologics and Biosimilars Sales in Value by Region (2025-2030)
4.3.3 Global Biologics and Biosimilars Sales (Volume & Value), Price and Gross Margin (2025-2030)
5 BIOLOGICS AND BIOSIMILARS BY APPLICATION
5.1 Biologics and Biosimilars Market by Application
5.1.1 Tumor
5.1.2 Diabetes
5.1.3 Cardiovascular
5.1.4 Hemophilia
5.1.5 Others
5.2 Global Biologics and Biosimilars Market Size by Application
5.2.1 Global Biologics and Biosimilars Market Size Overview by Application (2019-2030)
5.2.2 Global Biologics and Biosimilars Historic Market Size Review by Application (2019-2024)
5.2.3 Global Biologics and Biosimilars Forecasted Market Size by Application (2025-2030)
5.3 Key Regions Market Size by Application
5.3.1 North America Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
5.3.2 Europe Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
5.3.3 Asia-Pacific Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
5.3.4 Latin America Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
5.3.5 Middle East and Africa Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
6 COMPANY PROFILES
6.1 Roche
6.1.1 Roche Comapny Information
6.1.2 Roche Business Overview
6.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Biologics and Biosimilars Product Portfolio
6.1.5 Roche Recent Developments
6.2 Amgen
6.2.1 Amgen Comapny Information
6.2.2 Amgen Business Overview
6.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Biologics and Biosimilars Product Portfolio
6.2.5 Amgen Recent Developments
6.3 AbbVie
6.3.1 AbbVie Comapny Information
6.3.2 AbbVie Business Overview
6.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AbbVie Biologics and Biosimilars Product Portfolio
6.3.5 AbbVie Recent Developments
6.4 Sanofi-Aventis
6.4.1 Sanofi-Aventis Comapny Information
6.4.2 Sanofi-Aventis Business Overview
6.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
6.4.5 Sanofi-Aventis Recent Developments
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Comapny Information
6.5.2 Johnson & Johnson Business Overview
6.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
6.5.5 Johnson & Johnson Recent Developments
6.6 Pfizer
6.6.1 Pfizer Comapny Information
6.6.2 Pfizer Business Overview
6.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Pfizer Biologics and Biosimilars Product Portfolio
6.6.5 Pfizer Recent Developments
6.7 Novo Nordisk
6.7.1 Novo Nordisk Comapny Information
6.7.2 Novo Nordisk Business Overview
6.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
6.7.5 Novo Nordisk Recent Developments
6.8 Eli Lilly
6.8.1 Eli Lilly Comapny Information
6.8.2 Eli Lilly Business Overview
6.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
6.8.5 Eli Lilly Recent Developments
6.9 Novartis
6.9.1 Novartis Comapny Information
6.9.2 Novartis Business Overview
6.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Novartis Biologics and Biosimilars Product Portfolio
6.9.5 Novartis Recent Developments
6.10 Merck
6.10.1 Merck Comapny Information
6.10.2 Merck Business Overview
6.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Merck Biologics and Biosimilars Product Portfolio
6.10.5 Merck Recent Developments
6.11 3sbio
6.11.1 3sbio Comapny Information
6.11.2 3sbio Business Overview
6.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.11.4 3sbio Biologics and Biosimilars Product Portfolio
6.11.5 3sbio Recent Developments
6.12 Changchun High Tech
6.12.1 Changchun High Tech Comapny Information
6.12.2 Changchun High Tech Business Overview
6.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
6.12.5 Changchun High Tech Recent Developments
6.13 CP Guojian
6.13.1 CP Guojian Comapny Information
6.13.2 CP Guojian Business Overview
6.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
6.13.5 CP Guojian Recent Developments
6.14 Biotech
6.14.1 Biotech Comapny Information
6.14.2 Biotech Business Overview
6.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Biotech Biologics and Biosimilars Product Portfolio
6.14.5 Biotech Recent Developments
6.15 Gelgen
6.15.1 Gelgen Comapny Information
6.15.2 Gelgen Business Overview
6.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Gelgen Biologics and Biosimilars Product Portfolio
6.15.5 Gelgen Recent Developments
6.16 Innovent
6.16.1 Innovent Comapny Information
6.16.2 Innovent Business Overview
6.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Innovent Biologics and Biosimilars Product Portfolio
6.16.5 Innovent Recent Developments
6.17 Dong Bao
6.17.1 Dong Bao Comapny Information
6.17.2 Dong Bao Business Overview
6.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
6.17.5 Dong Bao Recent Developments
6.18 Ganlee
6.18.1 Ganlee Comapny Information
6.18.2 Ganlee Business Overview
6.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Ganlee Biologics and Biosimilars Product Portfolio
6.18.5 Ganlee Recent Developments
6.19 United Laboratories
6.19.1 United Laboratories Comapny Information
6.19.2 United Laboratories Business Overview
6.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
6.19.5 United Laboratories Recent Developments
7 NORTH AMERICA BY COUNTRY
7.1 North America Biologics and Biosimilars Sales by Country
7.1.1 North America Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.1.2 North America Biologics and Biosimilars Sales by Country (2019-2024)
7.1.3 North America Biologics and Biosimilars Sales Forecast by Country (2025-2030)
7.2 North America Biologics and Biosimilars Market Size by Country
7.2.1 North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2.2 North America Biologics and Biosimilars Market Size by Country (2019-2024)
7.2.3 North America Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
8 EUROPE BY COUNTRY
8.1 Europe Biologics and Biosimilars Sales by Country
8.1.1 Europe Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.1.2 Europe Biologics and Biosimilars Sales by Country (2019-2024)
8.1.3 Europe Biologics and Biosimilars Sales Forecast by Country (2025-2030)
8.2 Europe Biologics and Biosimilars Market Size by Country
8.2.1 Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2.2 Europe Biologics and Biosimilars Market Size by Country (2019-2024)
8.2.3 Europe Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
9 ASIA-PACIFIC BY COUNTRY
9.1 Asia-Pacific Biologics and Biosimilars Sales by Country
9.1.1 Asia-Pacific Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.1.2 Asia-Pacific Biologics and Biosimilars Sales by Country (2019-2024)
9.1.3 Asia-Pacific Biologics and Biosimilars Sales Forecast by Country (2025-2030)
9.2 Asia-Pacific Biologics and Biosimilars Market Size by Country
9.2.1 Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2.2 Asia-Pacific Biologics and Biosimilars Market Size by Country (2019-2024)
9.2.3 Asia-Pacific Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
10 LATIN AMERICA BY COUNTRY
10.1 Latin America Biologics and Biosimilars Sales by Country
10.1.1 Latin America Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.1.2 Latin America Biologics and Biosimilars Sales by Country (2019-2024)
10.1.3 Latin America Biologics and Biosimilars Sales Forecast by Country (2025-2030)
10.2 Latin America Biologics and Biosimilars Market Size by Country
10.2.1 Latin America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2.2 Latin America Biologics and Biosimilars Market Size by Country (2019-2024)
10.2.3 Latin America Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
11 MIDDLE EAST AND AFRICA BY COUNTRY
11.1 Middle East and Africa Biologics and Biosimilars Sales by Country
11.1.1 Middle East and Africa Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.1.2 Middle East and Africa Biologics and Biosimilars Sales by Country (2019-2024)
11.1.3 Middle East and Africa Biologics and Biosimilars Sales Forecast by Country (2025-2030)
11.2 Middle East and Africa Biologics and Biosimilars Market Size by Country
11.2.1 Middle East and Africa Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2.2 Middle East and Africa Biologics and Biosimilars Market Size by Country (2019-2024)
11.2.3 Middle East and Africa Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
12 VALUE CHAIN AND SALES CHANNELS ANALYSIS
12.1 Biologics and Biosimilars Value Chain Analysis
12.1.1 Biologics and Biosimilars Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Biologics and Biosimilars Production Mode & Process
12.2 Biologics and Biosimilars Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Biologics and Biosimilars Distributors
12.2.3 Biologics and Biosimilars Customers
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Biologics and Biosimilars Market Size Estimates and Forecasts (2019-2030)
1.2.2 Global Biologics and Biosimilars Sales Estimates and Forecasts (2019-2030)
1.3 Biologics and Biosimilars Market by Type
1.3.1 Monoclonal Antibodies
1.3.2 Interferon
1.3.3 Erythropoietin
1.3.4 Insulin
1.3.5 Vaccines
1.3.6 Others
1.4 Global Biologics and Biosimilars Market Size by Type
1.4.1 Global Biologics and Biosimilars Market Size Overview by Type (2019-2030)
1.4.2 Global Biologics and Biosimilars Historic Market Size Review by Type (2019-2024)
1.4.3 Global Biologics and Biosimilars Forecasted Market Size by Type (2025-2030)
1.5 Key Regions Market Size by Type
1.5.1 North America Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
1.5.2 Europe Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
1.5.3 Asia-Pacific Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
1.5.4 Latin America Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
1.5.5 Middle East and Africa Biologics and Biosimilars Sales Breakdown by Type (2019-2024)
2 GLOBAL MARKET DYNAMICS
2.1 Biologics and Biosimilars Industry Trends
2.2 Biologics and Biosimilars Industry Drivers
2.3 Biologics and Biosimilars Industry Opportunities and Challenges
2.4 Biologics and Biosimilars Industry Restraints
3 MARKET COMPETITIVE LANDSCAPE BY COMPANY
3.1 Global Top Players by Biologics and Biosimilars Revenue (2019-2024)
3.2 Global Top Players by Biologics and Biosimilars Sales (2019-2024)
3.3 Global Top Players by Biologics and Biosimilars Price (2019-2024)
3.4 Global Biologics and Biosimilars Industry Company Ranking, 2022 VS 2023 VS 2024
3.5 Global Biologics and Biosimilars Key Company Manufacturing Sites & Headquarters
3.6 Global Biologics and Biosimilars Company, Product Type & Application
3.7 Global Biologics and Biosimilars Company Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Biologics and Biosimilars Market CR5 and HHI
3.8.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2023
3.8.3 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier
4 BIOLOGICS AND BIOSIMILARS REGIONAL STATUS AND OUTLOOK
4.1 Global Biologics and Biosimilars Market Size and CAGR by Region: 2019 VS 2023 VS 2030
4.2 Global Biologics and Biosimilars Historic Market Size by Region
4.2.1 Global Biologics and Biosimilars Sales in Volume by Region (2019-2024)
4.2.2 Global Biologics and Biosimilars Sales in Value by Region (2019-2024)
4.2.3 Global Biologics and Biosimilars Sales (Volume & Value), Price and Gross Margin (2019-2024)
4.3 Global Biologics and Biosimilars Forecasted Market Size by Region
4.3.1 Global Biologics and Biosimilars Sales in Volume by Region (2025-2030)
4.3.2 Global Biologics and Biosimilars Sales in Value by Region (2025-2030)
4.3.3 Global Biologics and Biosimilars Sales (Volume & Value), Price and Gross Margin (2025-2030)
5 BIOLOGICS AND BIOSIMILARS BY APPLICATION
5.1 Biologics and Biosimilars Market by Application
5.1.1 Tumor
5.1.2 Diabetes
5.1.3 Cardiovascular
5.1.4 Hemophilia
5.1.5 Others
5.2 Global Biologics and Biosimilars Market Size by Application
5.2.1 Global Biologics and Biosimilars Market Size Overview by Application (2019-2030)
5.2.2 Global Biologics and Biosimilars Historic Market Size Review by Application (2019-2024)
5.2.3 Global Biologics and Biosimilars Forecasted Market Size by Application (2025-2030)
5.3 Key Regions Market Size by Application
5.3.1 North America Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
5.3.2 Europe Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
5.3.3 Asia-Pacific Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
5.3.4 Latin America Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
5.3.5 Middle East and Africa Biologics and Biosimilars Sales Breakdown by Application (2019-2024)
6 COMPANY PROFILES
6.1 Roche
6.1.1 Roche Comapny Information
6.1.2 Roche Business Overview
6.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Biologics and Biosimilars Product Portfolio
6.1.5 Roche Recent Developments
6.2 Amgen
6.2.1 Amgen Comapny Information
6.2.2 Amgen Business Overview
6.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Biologics and Biosimilars Product Portfolio
6.2.5 Amgen Recent Developments
6.3 AbbVie
6.3.1 AbbVie Comapny Information
6.3.2 AbbVie Business Overview
6.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AbbVie Biologics and Biosimilars Product Portfolio
6.3.5 AbbVie Recent Developments
6.4 Sanofi-Aventis
6.4.1 Sanofi-Aventis Comapny Information
6.4.2 Sanofi-Aventis Business Overview
6.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
6.4.5 Sanofi-Aventis Recent Developments
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Comapny Information
6.5.2 Johnson & Johnson Business Overview
6.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
6.5.5 Johnson & Johnson Recent Developments
6.6 Pfizer
6.6.1 Pfizer Comapny Information
6.6.2 Pfizer Business Overview
6.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Pfizer Biologics and Biosimilars Product Portfolio
6.6.5 Pfizer Recent Developments
6.7 Novo Nordisk
6.7.1 Novo Nordisk Comapny Information
6.7.2 Novo Nordisk Business Overview
6.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
6.7.5 Novo Nordisk Recent Developments
6.8 Eli Lilly
6.8.1 Eli Lilly Comapny Information
6.8.2 Eli Lilly Business Overview
6.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
6.8.5 Eli Lilly Recent Developments
6.9 Novartis
6.9.1 Novartis Comapny Information
6.9.2 Novartis Business Overview
6.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Novartis Biologics and Biosimilars Product Portfolio
6.9.5 Novartis Recent Developments
6.10 Merck
6.10.1 Merck Comapny Information
6.10.2 Merck Business Overview
6.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Merck Biologics and Biosimilars Product Portfolio
6.10.5 Merck Recent Developments
6.11 3sbio
6.11.1 3sbio Comapny Information
6.11.2 3sbio Business Overview
6.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.11.4 3sbio Biologics and Biosimilars Product Portfolio
6.11.5 3sbio Recent Developments
6.12 Changchun High Tech
6.12.1 Changchun High Tech Comapny Information
6.12.2 Changchun High Tech Business Overview
6.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
6.12.5 Changchun High Tech Recent Developments
6.13 CP Guojian
6.13.1 CP Guojian Comapny Information
6.13.2 CP Guojian Business Overview
6.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
6.13.5 CP Guojian Recent Developments
6.14 Biotech
6.14.1 Biotech Comapny Information
6.14.2 Biotech Business Overview
6.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Biotech Biologics and Biosimilars Product Portfolio
6.14.5 Biotech Recent Developments
6.15 Gelgen
6.15.1 Gelgen Comapny Information
6.15.2 Gelgen Business Overview
6.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Gelgen Biologics and Biosimilars Product Portfolio
6.15.5 Gelgen Recent Developments
6.16 Innovent
6.16.1 Innovent Comapny Information
6.16.2 Innovent Business Overview
6.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Innovent Biologics and Biosimilars Product Portfolio
6.16.5 Innovent Recent Developments
6.17 Dong Bao
6.17.1 Dong Bao Comapny Information
6.17.2 Dong Bao Business Overview
6.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
6.17.5 Dong Bao Recent Developments
6.18 Ganlee
6.18.1 Ganlee Comapny Information
6.18.2 Ganlee Business Overview
6.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Ganlee Biologics and Biosimilars Product Portfolio
6.18.5 Ganlee Recent Developments
6.19 United Laboratories
6.19.1 United Laboratories Comapny Information
6.19.2 United Laboratories Business Overview
6.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
6.19.5 United Laboratories Recent Developments
7 NORTH AMERICA BY COUNTRY
7.1 North America Biologics and Biosimilars Sales by Country
7.1.1 North America Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.1.2 North America Biologics and Biosimilars Sales by Country (2019-2024)
7.1.3 North America Biologics and Biosimilars Sales Forecast by Country (2025-2030)
7.2 North America Biologics and Biosimilars Market Size by Country
7.2.1 North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2.2 North America Biologics and Biosimilars Market Size by Country (2019-2024)
7.2.3 North America Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
8 EUROPE BY COUNTRY
8.1 Europe Biologics and Biosimilars Sales by Country
8.1.1 Europe Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.1.2 Europe Biologics and Biosimilars Sales by Country (2019-2024)
8.1.3 Europe Biologics and Biosimilars Sales Forecast by Country (2025-2030)
8.2 Europe Biologics and Biosimilars Market Size by Country
8.2.1 Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2.2 Europe Biologics and Biosimilars Market Size by Country (2019-2024)
8.2.3 Europe Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
9 ASIA-PACIFIC BY COUNTRY
9.1 Asia-Pacific Biologics and Biosimilars Sales by Country
9.1.1 Asia-Pacific Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.1.2 Asia-Pacific Biologics and Biosimilars Sales by Country (2019-2024)
9.1.3 Asia-Pacific Biologics and Biosimilars Sales Forecast by Country (2025-2030)
9.2 Asia-Pacific Biologics and Biosimilars Market Size by Country
9.2.1 Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2.2 Asia-Pacific Biologics and Biosimilars Market Size by Country (2019-2024)
9.2.3 Asia-Pacific Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
10 LATIN AMERICA BY COUNTRY
10.1 Latin America Biologics and Biosimilars Sales by Country
10.1.1 Latin America Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.1.2 Latin America Biologics and Biosimilars Sales by Country (2019-2024)
10.1.3 Latin America Biologics and Biosimilars Sales Forecast by Country (2025-2030)
10.2 Latin America Biologics and Biosimilars Market Size by Country
10.2.1 Latin America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2.2 Latin America Biologics and Biosimilars Market Size by Country (2019-2024)
10.2.3 Latin America Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
11 MIDDLE EAST AND AFRICA BY COUNTRY
11.1 Middle East and Africa Biologics and Biosimilars Sales by Country
11.1.1 Middle East and Africa Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.1.2 Middle East and Africa Biologics and Biosimilars Sales by Country (2019-2024)
11.1.3 Middle East and Africa Biologics and Biosimilars Sales Forecast by Country (2025-2030)
11.2 Middle East and Africa Biologics and Biosimilars Market Size by Country
11.2.1 Middle East and Africa Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2.2 Middle East and Africa Biologics and Biosimilars Market Size by Country (2019-2024)
11.2.3 Middle East and Africa Biologics and Biosimilars Market Size Forecast by Country (2025-2030)
12 VALUE CHAIN AND SALES CHANNELS ANALYSIS
12.1 Biologics and Biosimilars Value Chain Analysis
12.1.1 Biologics and Biosimilars Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Biologics and Biosimilars Production Mode & Process
12.2 Biologics and Biosimilars Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Biologics and Biosimilars Distributors
12.2.3 Biologics and Biosimilars Customers
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
LIST OF TABLES
Table 1. Major Company of Monoclonal Antibodies
Table 2. Major Company of Interferon
Table 3. Major Company of Erythropoietin
Table 4. Major Company of Insulin
Table 5. Major Company of Vaccines
Table 6. Major Company of Others
Table 7. Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030) & (US$ Million)
Table 8. Global Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 9. Global Biologics and Biosimilars Sales Market Share in Volume by Type (2019-2024)
Table 10. Global Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 11. Global Biologics and Biosimilars Sales Market Share in Value by Type (2019-2024)
Table 12. Global Biologics and Biosimilars Price by Type (2019-2024) & (USD/Unit)
Table 13. Global Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 14. Global Biologics and Biosimilars Sales Market Share in Volume by Type (2025-2030)
Table 15. Global Biologics and Biosimilars Sales by Type (2025-2030) & (US$ Million)
Table 16. Global Biologics and Biosimilars Sales Market Share in Value by Type (2025-2030)
Table 17. Global Biologics and Biosimilars Price by Type (2025-2030) & (USD/Unit)
Table 18. North America Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 19. North America Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 20. Europe Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 21. Europe Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 22. Asia-Pacific Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 23. Asia-Pacific Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 24. Latin America Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 25. Latin America Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 26. Middle East and Africa Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 27. Middle East and Africa Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 28. Biologics and Biosimilars Industry Trends
Table 29. Biologics and Biosimilars Industry Drivers
Table 30. Biologics and Biosimilars Industry Opportunities and Challenges
Table 31. Biologics and Biosimilars Industry Restraints
Table 32. Global Biologics and Biosimilars Sales Revenue by Company (US$ Million) & (2019-2024)
Table 33. Global Biologics and Biosimilars Revenue Market Share by Company (2019-2024)
Table 34. Global Biologics and Biosimilars Sales by Company (2019-2024) & (K Units)
Table 35. Global Biologics and Biosimilars Sales Share by Company (2019-2024)
Table 36. Global Biologics and Biosimilars Market Price by Company (2019-2024) & (USD/Unit)
Table 37. Global Biologics and Biosimilars Industry Company Ranking, 2022 VS 2023 VS 2024
Table 38. Global Biologics and Biosimilars Key Company Manufacturing Sites & Headquarters
Table 39. Global Biologics and Biosimilars Company, Product Type & Application
Table 40. Global Biologics and Biosimilars Company Commercialization Time
Table 41. Global Company Market Concentration Ratio (CR5 and HHI)
Table 42. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 43. Global Biologics and Biosimilars Market Size Comparison by Region (US$ Million): 2019 VS 2023 VS 2030
Table 44. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)
Table 45. Global Biologics and Biosimilars Sales Market Share in Volume by Region (2019-2024)
Table 46. Global Biologics and Biosimilars Sales by Region (2019-2024) & (US$ Million)
Table 47. Global Biologics and Biosimilars Sales Market Share in Value by Region (2019-2024)
Table 48. Global Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 49. Global Biologics and Biosimilars Sales by Region (2025-2030) & (K Units)
Table 50. Global Biologics and Biosimilars Sales Market Share in Volume by Region (2025-2030)
Table 51. Global Biologics and Biosimilars Sales by Region (2025-2030) & (US$ Million)
Table 52. Global Biologics and Biosimilars Sales Market Share in Value by Region (2025-2030)
Table 53. Global Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2025-2030)
Table 54. Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030) & (US$ Million)
Table 55. Global Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 56. Global Biologics and Biosimilars Sales Market Share in Volume by Application (2019-2024)
Table 57. Global Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 58. Global Biologics and Biosimilars Sales Market Share in Value by Application (2019-2024)
Table 59. Global Biologics and Biosimilars Price by Application (2019-2024) & (USD/Unit)
Table 60. Global Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 61. Global Biologics and Biosimilars Sales Market Share in Volume by Application (2025-2030)
Table 62. Global Biologics and Biosimilars Sales by Application (2025-2030) & (US$ Million)
Table 63. Global Biologics and Biosimilars Sales Market Share in Value by Application (2025-2030)
Table 64. Global Biologics and Biosimilars Price by Application (2025-2030) & (USD/Unit)
Table 65. North America Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 66. North America Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 67. Europe Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 68. Europe Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 69. Asia-Pacific Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 70. Asia-Pacific Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 71. Latin America Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 72. Latin America Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 73. Middle East and Africa Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 74. Middle East and Africa Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 75. Roche Company Information
Table 76. Roche Business Overview
Table 77. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Roche Biologics and Biosimilars Product Portfolio
Table 79. Roche Recent Development
Table 80. Amgen Company Information
Table 81. Amgen Business Overview
Table 82. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Amgen Biologics and Biosimilars Product Portfolio
Table 84. Amgen Recent Development
Table 85. AbbVie Company Information
Table 86. AbbVie Business Overview
Table 87. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. AbbVie Biologics and Biosimilars Product Portfolio
Table 89. AbbVie Recent Development
Table 90. Sanofi-Aventis Company Information
Table 91. Sanofi-Aventis Business Overview
Table 92. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 94. Sanofi-Aventis Recent Development
Table 95. Johnson & Johnson Company Information
Table 96. Johnson & Johnson Business Overview
Table 97. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 99. Johnson & Johnson Recent Development
Table 100. Pfizer Company Information
Table 101. Pfizer Business Overview
Table 102. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Pfizer Biologics and Biosimilars Product Portfolio
Table 104. Pfizer Recent Development
Table 105. Novo Nordisk Company Information
Table 106. Novo Nordisk Business Overview
Table 107. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 109. Novo Nordisk Recent Development
Table 110. Eli Lilly Company Information
Table 111. Eli Lilly Business Overview
Table 112. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 114. Eli Lilly Recent Development
Table 115. Novartis Company Information
Table 116. Novartis Business Overview
Table 117. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Novartis Biologics and Biosimilars Product Portfolio
Table 119. Novartis Recent Development
Table 120. Merck Company Information
Table 121. Merck Business Overview
Table 122. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. Merck Biologics and Biosimilars Product Portfolio
Table 124. Merck Recent Development
Table 125. 3sbio Company Information
Table 126. 3sbio Business Overview
Table 127. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. 3sbio Biologics and Biosimilars Product Portfolio
Table 129. 3sbio Recent Development
Table 130. Changchun High Tech Company Information
Table 131. Changchun High Tech Business Overview
Table 132. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 133. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 134. Changchun High Tech Recent Development
Table 135. CP Guojian Company Information
Table 136. CP Guojian Business Overview
Table 137. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 138. CP Guojian Biologics and Biosimilars Product Portfolio
Table 139. CP Guojian Recent Development
Table 140. Biotech Company Information
Table 141. Biotech Business Overview
Table 142. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 143. Biotech Biologics and Biosimilars Product Portfolio
Table 144. Biotech Recent Development
Table 145. Gelgen Company Information
Table 146. Gelgen Business Overview
Table 147. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 148. Gelgen Biologics and Biosimilars Product Portfolio
Table 149. Gelgen Recent Development
Table 150. Innovent Company Information
Table 151. Innovent Business Overview
Table 152. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 153. Innovent Biologics and Biosimilars Product Portfolio
Table 154. Innovent Recent Development
Table 155. Dong Bao Company Information
Table 156. Dong Bao Business Overview
Table 157. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 158. Dong Bao Biologics and Biosimilars Product Portfolio
Table 159. Dong Bao Recent Development
Table 160. Ganlee Company Information
Table 161. Ganlee Business Overview
Table 162. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 163. Ganlee Biologics and Biosimilars Product Portfolio
Table 164. Ganlee Recent Development
Table 165. United Laboratories Company Information
Table 166. United Laboratories Business Overview
Table 167. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 168. United Laboratories Biologics and Biosimilars Product Portfolio
Table 169. United Laboratories Recent Development
Table 170. North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2019 VS 2023 VS 2030
Table 171. North America Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 172. North America Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 173. North America Biologics and Biosimilars Sales Forecast by Country (2025-2030) & (K Units)
Table 174. North America Biologics and Biosimilars Sales Market Share Forecast by Country (2025-2030)
Table 175. North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 176. North America Biologics and Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 177. North America Biologics and Biosimilars Market Share by Country (2019-2024)
Table 178. North America Biologics and Biosimilars Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 179. North America Biologics and Biosimilars Market Share Forecast by Country (2025-2030)
Table 180. Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2019 VS 2023 VS 2030
Table 181. Europe Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 182. Europe Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 183. Europe Biologics and Biosimilars Sales Forecast by Country (2025-2030) & (K Units)
Table 184. Europe Biologics and Biosimilars Sales Market Share Forecast by Country (2025-2030)
Table 185. Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 186. Europe Biologics and Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 187. Europe Biologics and Biosimilars Market Share by Country (2019-2024)
Table 188. Europe Biologics and Biosimilars Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 189. Europe Biologics and Biosimilars Market Share Forecast by Country (2025-2030)
Table 190. Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2019 VS 2023 VS 2030
Table 191. Asia-Pacific Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 192. Asia-Pacific Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 193. Asia-Pacific Biologics and Biosimilars Sales Forecast by Country (2025-2030) & (K Units)
Table 194. Asia-Pacific Biologics and Biosimilars Sales Market Share Forecast by Country (2025-2030)
Table 195. Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 196. Asia-Pacific Biologics and Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 197. Asia-Pacific Biologics and Biosimilars Market Share by Country (2019-2024)
Table 198. Asia-Pacific Biologics and Biosimilars Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 199. Asia-Pacific Biologics and Biosimilars Market Share Forecast by Country (2025-2030)
Table 200. Latin America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2019 VS 2023 VS 2030
Table 201. Latin America Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 202. Latin America Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 203. Latin America Biologics and Biosimilars Sales Forecast by Country (2025-2030) & (K Units)
Table 204. Latin America Biologics and Biosimilars Sales Market Share Forecast by Country (2025-2030)
Table 205. Latin America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 206. Latin America Biologics and Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 207. Latin America Biologics and Biosimilars Market Share by Country (2019-2024)
Table 208. Latin America Biologics and Biosimilars Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 209. Latin America Biologics and Biosimilars Market Share Forecast by Country (2025-2
Table 1. Major Company of Monoclonal Antibodies
Table 2. Major Company of Interferon
Table 3. Major Company of Erythropoietin
Table 4. Major Company of Insulin
Table 5. Major Company of Vaccines
Table 6. Major Company of Others
Table 7. Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030) & (US$ Million)
Table 8. Global Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 9. Global Biologics and Biosimilars Sales Market Share in Volume by Type (2019-2024)
Table 10. Global Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 11. Global Biologics and Biosimilars Sales Market Share in Value by Type (2019-2024)
Table 12. Global Biologics and Biosimilars Price by Type (2019-2024) & (USD/Unit)
Table 13. Global Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 14. Global Biologics and Biosimilars Sales Market Share in Volume by Type (2025-2030)
Table 15. Global Biologics and Biosimilars Sales by Type (2025-2030) & (US$ Million)
Table 16. Global Biologics and Biosimilars Sales Market Share in Value by Type (2025-2030)
Table 17. Global Biologics and Biosimilars Price by Type (2025-2030) & (USD/Unit)
Table 18. North America Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 19. North America Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 20. Europe Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 21. Europe Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 22. Asia-Pacific Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 23. Asia-Pacific Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 24. Latin America Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 25. Latin America Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 26. Middle East and Africa Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 27. Middle East and Africa Biologics and Biosimilars Sales by Type (2019-2024) & (US$ Million)
Table 28. Biologics and Biosimilars Industry Trends
Table 29. Biologics and Biosimilars Industry Drivers
Table 30. Biologics and Biosimilars Industry Opportunities and Challenges
Table 31. Biologics and Biosimilars Industry Restraints
Table 32. Global Biologics and Biosimilars Sales Revenue by Company (US$ Million) & (2019-2024)
Table 33. Global Biologics and Biosimilars Revenue Market Share by Company (2019-2024)
Table 34. Global Biologics and Biosimilars Sales by Company (2019-2024) & (K Units)
Table 35. Global Biologics and Biosimilars Sales Share by Company (2019-2024)
Table 36. Global Biologics and Biosimilars Market Price by Company (2019-2024) & (USD/Unit)
Table 37. Global Biologics and Biosimilars Industry Company Ranking, 2022 VS 2023 VS 2024
Table 38. Global Biologics and Biosimilars Key Company Manufacturing Sites & Headquarters
Table 39. Global Biologics and Biosimilars Company, Product Type & Application
Table 40. Global Biologics and Biosimilars Company Commercialization Time
Table 41. Global Company Market Concentration Ratio (CR5 and HHI)
Table 42. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 43. Global Biologics and Biosimilars Market Size Comparison by Region (US$ Million): 2019 VS 2023 VS 2030
Table 44. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)
Table 45. Global Biologics and Biosimilars Sales Market Share in Volume by Region (2019-2024)
Table 46. Global Biologics and Biosimilars Sales by Region (2019-2024) & (US$ Million)
Table 47. Global Biologics and Biosimilars Sales Market Share in Value by Region (2019-2024)
Table 48. Global Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 49. Global Biologics and Biosimilars Sales by Region (2025-2030) & (K Units)
Table 50. Global Biologics and Biosimilars Sales Market Share in Volume by Region (2025-2030)
Table 51. Global Biologics and Biosimilars Sales by Region (2025-2030) & (US$ Million)
Table 52. Global Biologics and Biosimilars Sales Market Share in Value by Region (2025-2030)
Table 53. Global Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2025-2030)
Table 54. Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030) & (US$ Million)
Table 55. Global Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 56. Global Biologics and Biosimilars Sales Market Share in Volume by Application (2019-2024)
Table 57. Global Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 58. Global Biologics and Biosimilars Sales Market Share in Value by Application (2019-2024)
Table 59. Global Biologics and Biosimilars Price by Application (2019-2024) & (USD/Unit)
Table 60. Global Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 61. Global Biologics and Biosimilars Sales Market Share in Volume by Application (2025-2030)
Table 62. Global Biologics and Biosimilars Sales by Application (2025-2030) & (US$ Million)
Table 63. Global Biologics and Biosimilars Sales Market Share in Value by Application (2025-2030)
Table 64. Global Biologics and Biosimilars Price by Application (2025-2030) & (USD/Unit)
Table 65. North America Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 66. North America Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 67. Europe Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 68. Europe Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 69. Asia-Pacific Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 70. Asia-Pacific Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 71. Latin America Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 72. Latin America Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 73. Middle East and Africa Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 74. Middle East and Africa Biologics and Biosimilars Sales by Application (2019-2024) & (US$ Million)
Table 75. Roche Company Information
Table 76. Roche Business Overview
Table 77. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Roche Biologics and Biosimilars Product Portfolio
Table 79. Roche Recent Development
Table 80. Amgen Company Information
Table 81. Amgen Business Overview
Table 82. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Amgen Biologics and Biosimilars Product Portfolio
Table 84. Amgen Recent Development
Table 85. AbbVie Company Information
Table 86. AbbVie Business Overview
Table 87. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. AbbVie Biologics and Biosimilars Product Portfolio
Table 89. AbbVie Recent Development
Table 90. Sanofi-Aventis Company Information
Table 91. Sanofi-Aventis Business Overview
Table 92. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 94. Sanofi-Aventis Recent Development
Table 95. Johnson & Johnson Company Information
Table 96. Johnson & Johnson Business Overview
Table 97. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 99. Johnson & Johnson Recent Development
Table 100. Pfizer Company Information
Table 101. Pfizer Business Overview
Table 102. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Pfizer Biologics and Biosimilars Product Portfolio
Table 104. Pfizer Recent Development
Table 105. Novo Nordisk Company Information
Table 106. Novo Nordisk Business Overview
Table 107. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 109. Novo Nordisk Recent Development
Table 110. Eli Lilly Company Information
Table 111. Eli Lilly Business Overview
Table 112. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 114. Eli Lilly Recent Development
Table 115. Novartis Company Information
Table 116. Novartis Business Overview
Table 117. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Novartis Biologics and Biosimilars Product Portfolio
Table 119. Novartis Recent Development
Table 120. Merck Company Information
Table 121. Merck Business Overview
Table 122. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. Merck Biologics and Biosimilars Product Portfolio
Table 124. Merck Recent Development
Table 125. 3sbio Company Information
Table 126. 3sbio Business Overview
Table 127. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. 3sbio Biologics and Biosimilars Product Portfolio
Table 129. 3sbio Recent Development
Table 130. Changchun High Tech Company Information
Table 131. Changchun High Tech Business Overview
Table 132. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 133. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 134. Changchun High Tech Recent Development
Table 135. CP Guojian Company Information
Table 136. CP Guojian Business Overview
Table 137. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 138. CP Guojian Biologics and Biosimilars Product Portfolio
Table 139. CP Guojian Recent Development
Table 140. Biotech Company Information
Table 141. Biotech Business Overview
Table 142. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 143. Biotech Biologics and Biosimilars Product Portfolio
Table 144. Biotech Recent Development
Table 145. Gelgen Company Information
Table 146. Gelgen Business Overview
Table 147. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 148. Gelgen Biologics and Biosimilars Product Portfolio
Table 149. Gelgen Recent Development
Table 150. Innovent Company Information
Table 151. Innovent Business Overview
Table 152. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 153. Innovent Biologics and Biosimilars Product Portfolio
Table 154. Innovent Recent Development
Table 155. Dong Bao Company Information
Table 156. Dong Bao Business Overview
Table 157. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 158. Dong Bao Biologics and Biosimilars Product Portfolio
Table 159. Dong Bao Recent Development
Table 160. Ganlee Company Information
Table 161. Ganlee Business Overview
Table 162. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 163. Ganlee Biologics and Biosimilars Product Portfolio
Table 164. Ganlee Recent Development
Table 165. United Laboratories Company Information
Table 166. United Laboratories Business Overview
Table 167. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 168. United Laboratories Biologics and Biosimilars Product Portfolio
Table 169. United Laboratories Recent Development
Table 170. North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2019 VS 2023 VS 2030
Table 171. North America Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 172. North America Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 173. North America Biologics and Biosimilars Sales Forecast by Country (2025-2030) & (K Units)
Table 174. North America Biologics and Biosimilars Sales Market Share Forecast by Country (2025-2030)
Table 175. North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 176. North America Biologics and Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 177. North America Biologics and Biosimilars Market Share by Country (2019-2024)
Table 178. North America Biologics and Biosimilars Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 179. North America Biologics and Biosimilars Market Share Forecast by Country (2025-2030)
Table 180. Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2019 VS 2023 VS 2030
Table 181. Europe Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 182. Europe Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 183. Europe Biologics and Biosimilars Sales Forecast by Country (2025-2030) & (K Units)
Table 184. Europe Biologics and Biosimilars Sales Market Share Forecast by Country (2025-2030)
Table 185. Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 186. Europe Biologics and Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 187. Europe Biologics and Biosimilars Market Share by Country (2019-2024)
Table 188. Europe Biologics and Biosimilars Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 189. Europe Biologics and Biosimilars Market Share Forecast by Country (2025-2030)
Table 190. Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2019 VS 2023 VS 2030
Table 191. Asia-Pacific Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 192. Asia-Pacific Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 193. Asia-Pacific Biologics and Biosimilars Sales Forecast by Country (2025-2030) & (K Units)
Table 194. Asia-Pacific Biologics and Biosimilars Sales Market Share Forecast by Country (2025-2030)
Table 195. Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 196. Asia-Pacific Biologics and Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 197. Asia-Pacific Biologics and Biosimilars Market Share by Country (2019-2024)
Table 198. Asia-Pacific Biologics and Biosimilars Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 199. Asia-Pacific Biologics and Biosimilars Market Share Forecast by Country (2025-2030)
Table 200. Latin America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2019 VS 2023 VS 2030
Table 201. Latin America Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 202. Latin America Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 203. Latin America Biologics and Biosimilars Sales Forecast by Country (2025-2030) & (K Units)
Table 204. Latin America Biologics and Biosimilars Sales Market Share Forecast by Country (2025-2030)
Table 205. Latin America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 206. Latin America Biologics and Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 207. Latin America Biologics and Biosimilars Market Share by Country (2019-2024)
Table 208. Latin America Biologics and Biosimilars Market Size Forecast by Country (2025-2030) & (US$ Million)
Table 209. Latin America Biologics and Biosimilars Market Share Forecast by Country (2025-2
